Allogeneic bone marrow transplantation is an essential therapy for acquired aplastic anemia, and its prognosis has recently improved. However, engraftment failure and graft-versus-host disease are potential fatal complications. Various risk factors of poor prognosis have been identified, such as patient age and human-leukocyte antigen disparity, but the relationship between donor age and prognosis is still unknown. Therefore, we performed a cohort study to compare the prognosis of unrelated bone marrow transplantation from younger and older donors using the registry database in Japan. We evaluated 427 patients (16-72 years old) with aplastic anemia who underwent bone marrow transplantation from younger (≤39 years, N=281) or older (≥40 years, N=146) unrelated donors. Overall survival of the older donor group was significantly inferior to that of the younger donor group (adjusted hazard ratio, 1.64; 95% confidence interval, 1.15-2.35; p < 0.01). The incidence of fatal infection was significantly higher in the older donor group (13.7% vs. 7.5%, p=0.03). Primary engraftment failure and acute graft-versus-host disease were significantly more frequent in the older donor group (9.7% vs. 5.0%; adjusted hazard ratio, 1.30; p = 0.01, and 27.1% vs. 19.7%; adjusted hazard ratio, 1.56; p=0.03, respectively). Acute graft-versus-host disease was related to worse prognosis in the whole cohort. This study showed the inferiority of older donors in aplastic anemia; thus, donor age should be emphasized when multiple donors are available. A large-scale prospective study is warranted to establish a better donor selection algorithm for bone marrow transplantation of aplastic anemia.
Introduction
Allogeneic hematopoietic cell transplantation is an effective and therefore indispensable therapy for acquired aplastic anemia (AA) in adults 1 . Patients with AA are eligible for transplant if they are under 40 years of age or when they are refractory to immunosuppressive therapy 1, 2 ; bone marrow transplantation (BMT) from a human leukocyte antigen (HLA)-matched sibling donor or an unrelated donor is selected according to the donor availability 2 . The prognosis of BMT for AA has recently improved and 5-year overall survival (OS) is as high as 72% (for younger patients ≤ 40 years old) and 53% (for older patients >40 years) 3 .
However, severe complications, such as engraftment failure, infection, and graft-versus-host disease (GVHD), are problems that need to be addressed in order to improve the overall prognosis of AA, especially for unrelated BMT 2, 3 . Various risk factors are reportedly associated with these complications and poor prognosis, such as older patient age, longer periods from diagnosis to transplantation, HLA-mismatched donors, and female donors [2] [3] [4] . In addition to them, biological speculation from previous literatures regarding hematopoietic stem cell repopulation and donor-derived T cell function have suggested that transplantation from older donors may result in a higher incidence of engraftment failure and acute GVHD (aGVHD), and as a result, increase transplant-related death and deteriorate OS. Hematopoietic stem cells from older donors have less efficiency to repopulate according to the murine studies 5, 6 , and grafts from older donors have a higher ratio of memory T cells to naïve T cells 7 ; increase of peripheral blood memory T cells has been shown to be related to the occurrence of aGVHD in human 8, 9 .
The influence of donor age in unrelated hematopoietic cell transplantation has long been discussed in various studies, and some of them have shown a relationship between older donor and worse prognosis [10] [11] [12] [13] [14] [15] . Most of these cohorts, however, were mainly composed of hematological malignancies, and AA cases were not included [11] [12] [13] [14] [15] or, if any, occupied only a small portion of the cohort 10 . AA should be analyzed independently from malignant diseases, especially with regard to engraftment and GVHD, because the incidence of graft failure is more often documented in AA, and 5 GVHD more directly impacts OS 2 . Moreover, engraftment and GVHD are closely related to pre-or post-transplant tumor load in hematological malignancies, which is irrelevant to AA patients [16] [17] [18] .
As far as we know, however, no studies have investigated donor age as a candidate of the risk factor for poor prognosis in transplantation for AA.
Therefore, we performed a cohort study to compare the prognosis of patients with AA who underwent BMT from younger donors versus older donors using the Japanese transplant registry database, particularly focusing on engraftment and GVHD. We focused on BMT from unrelated donors in order to avoid the correlation between the age of patients and that of donors; thus, BMT from related sibling donors were excluded because siblings tend to be born only a few years apart 10 .
Our study should provide important points of view in donor selection algorithms for BMT in patients with AA. Selection of conditioning regimens and GVHD prophylaxis is at the discretion of attending physicians in each institute, considering disease status, amounts of transfusions, patients' age, their performance status, the risk of infections, and so on (age of the donor is not usually taken into consideration). Donor-derived serum and/or erythrocytes were depleted from grafts in cases of mismatched ABO blood types, and grafts were transplanted without ex vivo T cell depletion. Our protocol complied with the Declaration of Helsinki, and it was approved by the TRUMP Data Management Committee and by the Ethics Committee of Kyoto University, where the study was performed. Patient information is anonymized, so consent is not required.
Methods

Inclusion criteria and clinical procedures in BMT
Data collection and definition of each covariate
From the registry database, we extracted data on basic pre-transplant characteristics and post-transplant clinical courses. Donors were categorized into two groups with respect to age (younger vs. older than the 75th percentile; the closest value which is the multiple of five was adopted as the cut-off point). Influence of the donor age was also analyzed treating it as a continuous variable. Conditioning regimens were summarized according to the definitions of myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC), which were consistent with those established in the RIC regimen workshop 21 . Data on the usage of anti-thymocyte or anti-T cell globulin (ATG) before and after BMT were also collected. Periods between diagnosis and BMT were calculated from the day of initial diagnosis of AA.
With respect to post-transplant clinical courses, engraftment of neutrophils and platelets was defined as the first of three consecutive days during which neutrophil and platelet counts were at least 500/μL and 5. 
Results
Patients' characteristics
We evaluated 427 patients aged 16- 
OS was significantly worse with BMT from older donors
The OS of the older donor group was inferior to that of the younger donor group (Figure 1 Among other variables, older age of patients (≥30 years; Supplemental Figure 2 ), ABO blood type major mismatch, GVHD prophylaxis with cyclosporine, and BMT before 2006 were associated with worse survival (p<0.1). In the multivariate analysis including these factors and the other known confounders (HLA disparity and conditioning regimens), the older donor group showed significantly higher overall mortality (HR, 1.64; 95%CI, 1.15-2.25; p<0.01; Table 2 ).
This inferiority of OS in the older donor group (i.e. superiority in the younger donor group) was observed in each subgroup according to patient characteristics, with adjusted HRs being >1 in almost all subgroups ( Figure 2 ). This tendency was also confirmed when we confined the analysis to only recent cases (BMT after 2006) transplanted within 1 year after diagnosis using RIC regimen including ATG (N = 128; adjusted HR 2.03; 95%CI 0.94 -4.39; p = 0.07). Moreover, we compared OS between each donor group using Kaplan-Meier curves stratified by subgroups of patient age, HLA disparity, and conditioning regimens (Supplemental Figure 3) , because patient age is a known strong prognostic factor 2 , and HLA and conditioning regimens were statistically related to donor age in this cohort (Table 1) . Differences in survival according to donor age were also apparent in each subgroup.
When treating donor age as a continuous variable (supposing that the increase of one year in donor age has the same impact on OS), it is significantly related to poorer OS in multivariate analyses adjusted by confounding factors (HR, 1.03; 95%CI 1.01 -1.05 per one year increase of age, p < 0.01; HR, 1.36; 95%CI 1.08 -1.70 per 10 years increase of age; Supplemental Table 2 ), supporting our findings obtained by analyses treating donor age as the binary variable, and indicating that donor age is the independent risk factor.
The causes of mortality were summarized and compared between the two donor groups (Table 3 ). The major causes included infection and organ failure in both groups, and the incidence of fatal infections, especially bacterial infections, was significantly higher in the older donor group (13.7% vs. 7.5%, p=0.03). The reasons of mortality beyond 1 year after BMT were also summarized, because OS decreased during this period especially in the older donor group. GVHD, infections, and organ failures were more often documented in patients transplanted from older donors, though no significant differences were detected because of the relatively smaller number of patients (Supplemental Table 3 ).
Poorer engraftment and higher incidence of aGVHD were associated with older donors
In order to address the causes underlying the differences in OS and mortality between the younger and the older donor groups, we compared clinical courses between donor age groups, with particular focus on engraftment and GVHD because they are critical parameters that may determine the prognosis of patients with AA after BMT 2 .
As for engraftment, the older donor group showed a significantly lower proportion of neutrophil and platelet engraftment following BMT ( Figure 3A and Table 4 ). Primary engraftment failure was more frequently observed in the older donor group than in the younger donor group (9.7% vs. 5.0%, HR, 1.15; p < 0.01). Neutrophil engraftment or engraftment failure is still significantly higher in the older donor group after multivariate analyses adjusted for confounding factors such as patient age, HLA disparity, ABO disparity, harvested NCC, conditioning regimens, and GVHD prophylaxis ( Figure 3B ), while there was no significant difference in grade III-IV aGVHD between groups (8.3% vs. 6.9%; adjusted HR, 1.32; p=0.45); in addition, the incidence of cGVHD was almost the same in both groups (24.6% vs.
27.8%; adjusted HR, 0.91; p=0.66) ( Table 4 and Figure 3B ). 
Impacts of aGVHD on OS and its relationship to mortality
It is thought that the complication with aGVHD may directly result in poor OS in patients with AA because graft-versus-host reaction doesn't have such merit as graft-versus-leukemia effects observed in transplant for leukemia 17 . To confirm this hypothesis in our cohort, we determined OS regarding aGVHD as a time-dependent covariate 25 . As a result, aGVHD (grade II-IV) showed the tendency of worse prognosis in the whole cohort (adjusted HR, 1.42; 95%CI, 0.95-2.11; p=0.08) and in both donor age groups. Landmark analysis (on day 30 or day 60 after BMT) also showed a trend toward worse survival in patients with aGVHD (data not shown). Poor response to immunosuppressive therapies even in grade II aGVHD can support these data, and the higher incidence of aGVHD in the older donor group may partially account for the worse prognosis in this group due to infections and organ failures (Table 3 and Supplemental Table 3 ).
Discussion
This cohort study regarding donor age and prognosis of unrelated BMT for AA revealed three major findings: (1) OS in transplantation from older donors (40 years old or over) was significantly worse than that from younger donors; (2) neutrophil and platelet engraftment was suppressed and engraftment failure was more often documented following transplant from older donors; and (3) the older donor group had a higher incidence of aGVHD.
First, we clearly showed an inferior prognosis in the older donor group compared to the younger donor group. This result was confirmed by multivariate and various subgroup analyses, in order to exclude the influence of confounding factors such as patient age, HLA disparity, conditionings, and so on. Our data indicated that older donor age can be considered an independent risk factor for poor prognosis after unrelated BMT for AA irrespective of treating it as the binary covariate or the continuous covariate. It should be emphasized that donor age was not correlated with patient age, which is the strongest prognostic factor 2 , in our whole cohort (Supplemental Figure 1 ) or in any subgroup of patients' characteristics, such as sex, HLA disparity, conditioning regimens, GVHD prophylaxis, and year of BMT. As far as we know, relationship between donor age and prognosis has not yet been reported in regard to AA patients.
This difference in prognosis can be explained in part by the significantly higher incidence of fatal infection (especially bacterial infection) in the older donor group (Table 3) , which may have been due to insufficiency or dysfunction of immune cells derived from older donor grafts. Actually, this speculation is supported by previous studies in mice indicating that recovery of the absolute number of lymphocytes in the early post-transplant period was delayed in recipients transplanted from older donors even after bone marrow engraftment, suggesting the delayed recovery of cytotoxic T cells and immunoglobulin-secreting B cells (leading to hypogammaglobulinemia) 26, 27 .
Moreover, suppression of neutrophil function was shown in neutrophils from aged donors due to the decrease in secondary messenger generation, such as diacylglycerol and inositol-triphosphate, and the defect in superoxide generation which is essential for bacterial killing 28 . Unfortunately, data on lymphocyte characteristics and neutrophil function were lacking in our dataset, but our epidemiological data and biological studies in mice suggest that controlling severe infection, especially that of bacteria, might be a key issue to improve prognosis following transplantation from older donors.
Next, we found that older donor grafts were related to a higher incidence of primary graft Poor engraftment with older donors has also been shown in murine transplant models 5, 6 , and this kind of "aging" in grafts from older donors may be related to age-associated modifications in DNA methylation patterns 29 and/or shorter length of telomeres in hematopoietic stem or progenitor cells from older donors 30 .
Finally, we showed a higher incidence of aGVHD in older donors in both analyses treating donor age as binary or continuous variables. This may be explained by the higher ratio of memory T cell to naïve T cell subsets in older people 7 ; recent clinical studies have showed that peripheral blood CD8 + effector memory T cells are closely associated with aGVHD in human 8, 9 , in contrast to previous findings in murine model 31 . Different gene-expression profiles regarding to GVHD such as transforming growth factor-β in CD4 + and CD8 + T cells were also shown in older donors 32 . In our cohort, all the grafts were injected without ex vivo T cell depletion; therefore, it may be speculated that massive amounts of antigen-experienced memory T cells (including those which can recognize and attack the recipient-specific major and/or minor histocompatibility antigens) were injected, especially in cases with older donors, which initiated allo-reaction leading to aGVHD.
Hyper-acute phase of aGVHD targeting bone marrow niche may induce, at the same time, engraftment failure in BMT from older donor 33 . These speculations suggest that appropriate usage of ATG should be helpful to overcome this disadvantage of choosing older donor-derived bone marrow grafts.
The impact of aGVHD on OS is another important point to be discussed. In transplantation for hematological malignancies, aGVHD, if not severe and beyond the control, can be an indicator for better survival because GVHD may guarantee the existence of graft-versus-tumor effects that can suppress post-transplant relapse 17 . In AA, however, we confirmed that GVHD, regardless of the severity, does not have any beneficial effects on patients and worsens prognosis; grade II-IV aGVHD was related to inferior OS in both donor age groups, and grade III-IV aGVHD increased mortality to an even greater extent (HR, 3.19; p<0.01). One of the explanations that account for such inferior survival is the refractoriness of aGVHD in our cohort; more than 30% of patients were refractory to the initial steroid therapy even in grade II aGVHD, and more than 60% of those with grade III -IV required secondary immunosuppressive therapies. Therefore, the higher incidence of aGVHD following BMT from older donors may also explain the worse prognosis in this group.
The number of patients for whom GVHD was selected as the main cause of mortality was small, and there was no difference between the donor age groups (Table 3) . It is suspected that most of the patients who experienced long term episodes of GVHD acquired fatal infection or organ dysfunction after continuous immunosuppressive status due to the nature of GVHD itself or its treatment 34, 35 . Among these patients, the main cause of mortality was indicated as infection or organ failure in our database.
In summary, we found the inferiority of older donors in unrelated BMT for AA compared to younger donors (treated as the binary covariate; 40 years or higher vs. 39 years or older, or the 15 continuous covariate), mainly because of the higher incidence of engraftment failure and aGVHD in the former group; these complications can induce fatal infections. This analysis suggests that donor age should be emphasized as a criterion when multiple unrelated donors are available for AA and recruitment of younger voluntary candidates for BMT donors should be more important. Our study, however, was retrospective in design and was conducted in a single country. In addition to that, due to the long period of patient recruitment, protocols were not necessarily compatible with the current guidelines in some patients; to transplant as soon as possible after diagnosis with the conditioning regimen including cyclophosphamide, ATG, and low-dose TBI is the widely recommended protocol 24 . We confirmed that our main results can be reproduced in the subgroup analyses of patients who were treated according to the current guidelines. Moreover, discussion regarding the choice of a younger unrelated donor and the older matched sibling donor is difficult to be covered by a retrospective study; therefore, large-scale international prospective studies are necessary to validate the results and to revise a donor selection algorithm in the future. 
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Figure 1
Supplemental Methods
Statistical analyses
Differences in pre-transplant patient characteristics and the causes of mortality between the younger and the older donor group were analyzed using the χ 2 -test or Student's t-test.
OS was calculated with the Kaplan-Meier method and compared using log-rank tests for each covariant related to pre-transplant patient characteristics. Factors with significance or borderline significance (p<0.1) in the univariate analysis and previously reported confounding factors (HLA disparity and conditioning regimens) were subjected to a multivariate analysis using the Cox proportional hazards model. Cumulative incidence of engraftment and GVHD was calculated using Gray's method and compared with Fine-Gray proportional models considering death or salvage transplantation (for engraftment failure) as a competing risk; hazard ratios (HRs) and p values were adjusted with potential confounding factors, such as patient age, HLA disparity, ABO disparity, harvested nucleated cell count (NCC), conditionings, and GVHD prophylaxis.
Statistical analyses were performed using Stata (version 13.1, Stata Corp LP, College Station, TX, USA). The alpha level of all tests and the p value were set at 0.05.
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Supplemental Figure 3. Overall survival after BMT in each subgroup
OS is calculated with the Kaplan-Meier method in each subgroup of (A) patient age, (B) HLA disparity, and (C) conditioning regimens, because patient age is a known prognostic factor and HLA and conditioning regimens were closely related to donor age (Table 1) . Abbreviations; D, donor; and Pt, patient.
